Decision No. 376/QD-TTg approving the development program for pharmaceuticals industry until 2030
By 2025, to build 8 regions for sustainable exploitation of natural medicinal materials
The Decision No. 376/QD-TTg approving the Program on development the pharmaceutical industry and domestically produced medicinal materials to 2030, with a vision to 2045 is issued on March 17, 2021 by the Prime Minister.
The Program also aims to build 08 regions for sustainable exploitation of natural medicinal materials by 2025. To build 02 - 05 large-scale medicinal plant growing areas, each exploiting area or growing area having 01 - 02 chains of research, growing, processing and production of medicinal materials in compliance with the World Health Organization’s principles.
In order to achieve the above-mentioned targets, special incentives shall be applied to the research, transfer, and production of drug materials, especially drug materials of biological origin, and drug materials using domestic medicinal materials of high economic value.
Concurrently, investing in building and implementing the Center for Bioequivalence Testing and Clinical Testing, the Center for High-Tech Drugs, Drugs from Medicinal Materials and Traditional Drugs, and National Center for Research in Genetic Resources and Medicinal Material Seeds.
This Decision takes effect on the signing date.
For further details of the Decision 376/QD-TTg, Click here
translation of the Official Gazette of the Vietnam News Agency
THE PRIME MINISTER
THE SOCIALIST REPUBLIC OF VIETNAM
Hanoi, March 17, 2021
Approving the Program on development the pharmaceutical industry and domestically produced medicinal materials to 2030, with a vision to 2045
THE PRIME MINISTER
Pursuant to the June 19, 2015 Law on Organization of the Government; and the November 22, 2019 Law Amending and Supplementing a Number of Articles of the Law on Organization of the Government and the Law on Organization of Local Administration;
Pursuant to the April 6, 2016 Law on Pharmacy;
Pursuant to the June 17, 2020 Law on Investment;
Pursuant to October 25, 2017 Resolution No. 20-NQ/TW of the Sixth Plenum of the Party Central Committee, the XIIth Term, on intensifying the protection, care and improvement of people's health in the new situation;
Pursuant to the Government's Resolution No. 139/NQ-CP of December 31, 2017, promulgating the Government's Action Program to implement Resolution No. 20-NQ/TW of October 25, 2017, of the 6th Plenum of the Party Central Committee, the XIIth Term, on intensifying the protection, care and improvement of the people's health in the new situation;
At the proposal of the Minister of Health,
Article 1. To approve the Program on development of the pharmaceutical industry and domestically produced medicinal materials to 2030, with a vision to 2045 (below referred to as the Program) with the following contents:
I. DEVELOPMENT VIEWS
1. To prioritize the development of the pharmaceutical industry and domestic production of drug materials with high-level incentive and support mechanisms and policies in accordance with law.
2. To strongly attract investment resources for the development of the pharmaceutical industry, to attach importance to attracting foreign investment in the production of still patented brand-name drugs, specialty drugs, and generic drugs with high-tech dosage forms, vaccines, reference biological products and similar biological products.
The State shall give priority to investment in scientific research into and production of new drugs and high-quality drugs from medicinal materials, and development of production of national-branded drugs from medicinal materials.